{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:26:51Z","timestamp":1793406411973,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.jns.2017.04.039","type":"journal-article","created":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T17:47:19Z","timestamp":1493056039000},"page":"19-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs"],"prefix":"10.1016","volume":"378","author":[{"given":"Lars H.","family":"Markvardsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Harbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jns.2017.04.039_bb0005","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2008.02246.x","article-title":"EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases","volume":"15","author":"Elovaara","year":"2008","journal-title":"Eur. J. Neurol."},{"issue":"13","key":"10.1016\/j.jns.2017.04.039_bb0010","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1212\/WNL.0b013e31824de293","article-title":"Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"78","author":"Patwa","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2017.04.039_bb0015","author":"Shire"},{"key":"10.1016\/j.jns.2017.04.039_bb0020","author":"Octapharma"},{"key":"10.1016\/j.jns.2017.04.039_bb0025","author":"Behring"},{"key":"10.1016\/j.jns.2017.04.039_bb0030","author":"Shire"},{"issue":"5","key":"10.1016\/j.jns.2017.04.039_bb0035","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s10875-013-9876-3","article-title":"Bioavailability of IgG administered by the subcutaneous route","volume":"33","author":"Berger","year":"2013","journal-title":"J. Clin. Immunol."},{"issue":"2","key":"10.1016\/j.jns.2017.04.039_bb0040","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.clim.2011.01.006","article-title":"Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies","volume":"139","author":"Berger","year":"2011","journal-title":"Clin. Immunol."},{"issue":"6","key":"10.1016\/j.jns.2017.04.039_bb0045","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jaip.2013.09.012","article-title":"Adverse effects of IgG therapy","volume":"1","author":"Berger","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.jns.2017.04.039_bb0050","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/ene.12080","article-title":"Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy","volume":"20","author":"Markvardsen","year":"2013","journal-title":"Eur. J. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2017.04.039_bb0055","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ana.21737","article-title":"Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barre syndrome","volume":"66","author":"Kuitwaard","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2017.04.039_bb0060","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.84.14_supplement.P7.094","article-title":"Subcutaneous immunoglobulin (IgPRO20) for maintenance treatment in patients with multifocal motor neuropathy","volume":"84","author":"Katzberg","year":"2015","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2017.04.039_bb0065","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1529-8027.2009.00218.x","article-title":"Subcutaneous immunoglobulin therapy for multifocal motor neuropathy","volume":"14","author":"Eftimov","year":"2009","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"12","key":"10.1016\/j.jns.2017.04.039_bb0070","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/ene.12513","article-title":"Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy","volume":"21","author":"Markvardsen","year":"2014","journal-title":"Eur. J. Neurol."},{"issue":"15","key":"10.1016\/j.jns.2017.04.039_bb0075","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1212\/WNL.0b013e3181f735ce","article-title":"Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy","volume":"75","author":"Harbo","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2017.04.039_bb0080","article-title":"Subcutaneous immunoglobulin in CIDP and MMN: a different long-term clinical response?","author":"Cocito","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2017.04.039_bb0085","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/1756285614563056","article-title":"Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction","volume":"8","author":"Hadden","year":"2015","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"4","key":"10.1016\/j.jns.2017.04.039_bb0090","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/mus.21305","article-title":"Acute motor response following a single IVIG treatment course in chronic inflammatory demyelinating polyneuropathy","volume":"39","author":"Harbo","year":"2009","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.jns.2017.04.039_bb0095","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/bcpt.12428","article-title":"Headache and nausea after treatment with high-dose subcutaneous versus intravenous immunoglobulin","volume":"117","author":"Markvardsen","year":"2015","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.jns.2017.04.039_bb0100","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1046\/j.1537-2995.1980.20180125049.x","article-title":"Levels of anti-A and anti-B in commercial immune globulins","volume":"20","author":"Gordon","year":"1980","journal-title":"Transfusion"},{"issue":"Suppl. 2","key":"10.1016\/j.jns.2017.04.039_bb0105","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1111\/trf.13113","article-title":"The role of isoagglutinins in intravenous immunoglobulin-related hemolysis","volume":"55","author":"Bellac","year":"2015","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.jns.2017.04.039_bb0110","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/ene.12287","article-title":"Hemolytic anemia following high dose intravenous immunoglobulin in patients with chronic neurological disorders","volume":"21","author":"Markvardsen","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2017.04.039_bb0115","author":"Jakobsen"},{"issue":"10","key":"10.1016\/j.jns.2017.04.039_bb0120","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1111\/trf.13727","article-title":"Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy","volume":"56","author":"Markvardsen","year":"2016","journal-title":"Transfusion"},{"issue":"8946","key":"10.1016\/j.jns.2017.04.039_bb0125","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(95)90346-1","article-title":"Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs","volume":"345","author":"Gardulf","year":"1995","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jns.2017.04.039_bb0130","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s10198-004-0250-5","article-title":"Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance","volume":"6","author":"Hogy","year":"2005","journal-title":"Eur. J. Health Econ."},{"issue":"1","key":"10.1016\/j.jns.2017.04.039_bb0135","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-3148.2012.01201.x","article-title":"Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency","volume":"23","author":"Martin","year":"2013","journal-title":"Transfus. Med."},{"issue":"4","key":"10.1016\/j.jns.2017.04.039_bb0140","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1529-8027.2012.00444.x","article-title":"Economic and quality of life evaluation of different modalities of immunoglobulin therapy in chronic dysimmune neuropathies","volume":"17","author":"Cocito","year":"2012","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"7","key":"10.1016\/j.jns.2017.04.039_bb0145","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s10072-014-1632-9","article-title":"Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis","volume":"35","author":"Lazzaro","year":"2014","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jns.2017.04.039_bb0150","article-title":"Subcutaneous vs. intravenous immunoglobulin for chronic autoimmune neuropathies: a meta-analysis","volume":"20","author":"Racosta","year":"2016","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.1016\/j.jns.2017.04.039_bb0155","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00415-006-0258-0","article-title":"Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies","volume":"253","author":"Koller","year":"2006","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2017.04.039_bb0160","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/mus.20909","article-title":"Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy","volume":"37","author":"Lee","year":"2008","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.jns.2017.04.039_bb0165","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1529-8027.2011.00340.x","article-title":"The efficacy of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyneuropathy responders to intravenous immunoglobulin","volume":"16","author":"Cocito","year":"2011","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"1\u20132","key":"10.1016\/j.jns.2017.04.039_bb0170","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jns.2012.09.033","article-title":"Long-term treatment of Lewis-Sumner syndrome with subcutaneous immunoglobulin infusions","volume":"324","author":"Bayas","year":"2013","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.jns.2017.04.039_bb0175","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00421-011-1975-3","article-title":"Maximal isokinetic and isometric muscle strength of major muscle groups related to age, body mass, height, and sex in 178 healthy subjects","volume":"112","author":"Harbo","year":"2012","journal-title":"Eur. J. Appl. Physiol."},{"issue":"11","key":"10.1016\/j.jns.2017.04.039_bb0180","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00415-014-7444-2","article-title":"Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study","volume":"261","author":"Cocito","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2017.04.039_bb0185","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/ene.13218","article-title":"Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study","volume":"24","author":"Markvardsen","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2017.04.039_bb0190","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.12968\/bjon.2010.19.Sup1.47082","article-title":"Switching to Home-based SCIG for Multifocal Motor Neuropathy (MMN)","volume":"19","author":"Woodall Amanda","year":"2010","journal-title":"Br. J. Nurs."},{"issue":"5","key":"10.1016\/j.jns.2017.04.039_bb0195","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1468-1331.2009.02568.x","article-title":"Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial","volume":"16","author":"Harbo","year":"2009","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2017.04.039_bb0200","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1529-8027.2011.00330.x","article-title":"A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study","volume":"16","author":"Misbah","year":"2011","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"6","key":"10.1016\/j.jns.2017.04.039_bb0205","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10072-010-0352-z","article-title":"Subcutaneous immunoglobulin therapy for the treatment of multifocal motor neuropathy: a case report","volume":"31","author":"Dacci","year":"2010","journal-title":"Neurol. Sci."},{"issue":"8","key":"10.1016\/j.jns.2017.04.039_bb0210","first-page":"S21-1","article-title":"A comparison between intravenous and subcutmaneous immunogobulin","volume":"21","author":"Braine","year":"2012","journal-title":"Br J Nurs"},{"issue":"6","key":"10.1016\/j.jns.2017.04.039_bb0215","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med. Care"},{"issue":"11","key":"10.1016\/j.jns.2017.04.039_bb0220","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1007\/s10072-013-1426-5","article-title":"Improvement of quality of life in patients with chronic inflammatory demyelinating polyneuropathy shifting from 16 to 20% subcutaneous immunoglobulins","volume":"34","author":"Cocito","year":"2013","journal-title":"Neurol. Sci."},{"issue":"1","key":"10.1016\/j.jns.2017.04.039_bb0225","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-016-1466-2","article-title":"Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial","volume":"17","author":"van Schaik","year":"2016","journal-title":"Trials"},{"key":"10.1016\/j.jns.2017.04.039_bb0230","author":"Gelmont"},{"issue":"4","key":"10.1016\/j.jns.2017.04.039_bb0235","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/1756285615584739","article-title":"Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders","volume":"8","author":"Yoon","year":"2015","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17302721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17302721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T23:57:42Z","timestamp":1750204662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X17302721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":47,"alternative-id":["S0022510X17302721"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2017.04.039","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2017.04.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}